Pancreatic Cancer
Conditions
Keywords
real word study, irinotecan hydrochloride liposome injection II, pancreatic cancer
Brief summary
This study is a multi-center observational study.The start time for data collection is May 1, 2024. Patients' baseline and treatment data will be collected under informed concent. The purpose of this case registry study was to evaluate the safety and efficacy of irinotecan hydrochloride liposome injection II based therapy in Chinese patients with pancreatic cancer in the real world by collecting, understanding, and analyzing the etiology, clinical features, treatment pattern, treatment outcomes, and pharmacoeconomics changes in pancreatic cancer patients receiving this regimen.
Interventions
Irinotecan liposome II combination therapy regimen
Sponsors
Peking Union Medical College Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Patients with pancreatic ductal adenocarcinoma diagnosed by pathology or imaging; * Age ≥18 years old, male or female; * Patients receiving treatment based on irinotecan hydrochloride liposome injection II; * The subjects voluntarily joined the study and signed the informed consent.
Exclusion criteria
* Confirmed pregnant or lactating women; * The researchers determined that other conditions were not suitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| rwTEAE | 3 years | real word treatment emergent adverse event |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS | 3 years | real word overall survival |
| PFS | 3 years | real word progression free survival |
| ORR | 3 years | real word objective response rate |
| TTP | 3 years | real word time to progression |
| DCR | 3 years | real word disease control rate |
Countries
China
Contacts
Primary ContactTaiping Zhang, doctor
Outcome results
None listed